Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Captures Overall Composite Edge (45.2 HOLD vs 36.8 SELL), While VIVS Leads 3–2 on Growth & Valuation Pillars

ENTX Overall Winner 6-Pillar Tally: VIVS 3 – 2 ENTX (1 Tie) Matrix Metrics: VIVS 1 – 6 ENTX

As of Nov 19, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (45.2/100 HOLD vs. 36.8/100 SELL) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. VIVS trades at $0.29 (N/M Forward P/E, -10117.0% operating margin) versus ENTX at $3.28 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. VIVS 36.8/100 SELL) and 0.86β · 54% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs ENTX
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.28
+0.61% 1D
Market Cap $567.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.86β · 54% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $3.11 · SMA50: $2.92

6-Pillar Scorecard Institutional Category Breakdown (VIVS 3 – 2 ENTX)

Columns: Metric · VIVS · ENTX
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.6x N/M
2. Growth & Scale VIVS
Revenue Growth (YoY) -51.4% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $112,000 N/A
Market Cap $2.4M $567.7M
3. Profitability & Quality ENTX
Gross Margin N/A N/A
Operating Margin -10117.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -343.1% -20.3%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$11M EBITDA -$16M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.4M Net Cash $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 114.4% (33rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (1) vs ENTX (6)
Institutional Metric VIVS ENTX Criterion Row Edge
Market Capitalization
Scale
$2.4M $567.7M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-51.4% -100.0% Higher Growth VIVS
Operating Margin (TTM)
Profitability
-10117.0% 0.0% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-343.1% -20.3% Higher ROE ENTX
52-Week Range Position
Momentum
5% ($0–$3) 72% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 0.86β · 54% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 45.2 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
$112,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +57.15 pp
VIVS: +64.69% · ENTX: +7.54%
3M Horizon VIVS +0.37 pp
VIVS: +1.92% · ENTX: +1.55%
6M Horizon ENTX +236.52 pp
VIVS: -78.25% · ENTX: +158.27%
1Y Horizon ENTX +113.14 pp
VIVS: -86.99% · ENTX: +26.15%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VIVS Revenue ENTX Revenue VIVS Op. Margin ENTX Op. Margin Margin Leader
FY2019 $0M N/A -882.4% N/A VIVS
FY2020 $0M $0M -977.9% -3059.7% VIVS
FY2021 N/A $0M N/A -2139.6% ENTX
FY2022 $0M $0M -765.3% -9714.2% VIVS
FY2023 $0M N/A -4792.2% N/A VIVS
FY2024 $0M $0M -13840.4% -5295.6% ENTX
FY2025 $0M $0M -8761.1% -27450.0% VIVS
FY2026 $0M N/A -8768.7% N/A VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
82d in phase · OBV NEUTRAL
Current IV 114.4%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $567.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VIVS vs ENTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (45.2/100 HOLD vs. 36.8/100 SELL) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. VIVS trades at $0.29 (N/M Forward P/E, -10117.0% operating margin) versus ENTX at $3.28 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. VIVS 36.8/100 SELL) and 0.86β · 54% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VIVS leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VIVS cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus ENTX (-20.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, ENTX carries 114.4% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.86β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.